Shamburg News · 8-K filed Nov 16, 2026, 7:55 AM EST

Galectin Therapeutics Reports Q3 2026 Results and Provides Business Update

GALT · GALECTIN THERAPEUTICS INC

  • Earnings
  • Financing
  • Materiality: high

Galectin Therapeutics reported a net loss applicable to common stockholders of $3.6 million, or $(0.04) per share, for the quarter ended September 30, 2026, compared with $8.2 million, or $(0.13) per share, in the prior-year period. The company reported $11.7 million of cash and cash equivalents as of September 30, 2026, and stated it believes it has sufficient cash to fund planned operations through June 2027. The press release also disclosed that Chairman Richard E. Uihlein converted approximately $105.8 million of debt into 34,376,167 shares of common stock, effective July 31, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001140361-26-043989.

Written from the filing by Shamburg Markets. Figures are as reported by the company.